Physician profile
Patrick L Turner
NPI 1275899478
$441.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.96 · 2020: $117 · 2021: $213 · 2022: $34.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $129.59 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $61.63 | 2021 | |
| Amarin Pharma, INC. | $61.07 | 2020 | |
| Amgen INC. | $42.78 | 2021 | |
| Glaxosmithkline, LLC. | $38.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.66 | 2021 | |
| Boston Scientific Corporation | $18.65 | 2019 | |
| Novo Nordisk INC | $14.08 | 2020 | |
| Genentech USA, INC. | $12.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.82 | 2020 | |
| Merck Sharp & Dohme LLC | $11.51 | 2019 | |
| Allergan, INC. | $11.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.